Navigation Links
Soligenix Announces Formation of Pediatric Crohn's Disease Medical Advisory Board
Date:10/11/2011

h in Morristown, New Jersey. Certified by the American Board of Pediatrics in pediatric gastroenterology and nutrition, and by the National Board of Medical Examiners, Dr. Rosh has served as the National Chairman for Pediatric Education for the Crohn's and Colitis Foundation of America, the Vice Chairman of the American Academy of Pediatrics GI practice committee and the National Pediatric Endoscopy committee. He is on the Editorial Board of the Journal of Pediatric Gastroenterology and Nutrition and serves as a reviewer for various major scientific journals.  Additionally, Dr. Rosh is a Founder of the New Jersey Pediatric GI Society and a Fellow of the American College of Gastroenterology and the American Gastroenterological Association.  Dr. Rosh received his MD from the Albert Einstein College of Medicine in New York. His postdoctoral training included an internship and residency in the Babies Hospital–Columbia Presbyterian Medical Center Department of Pediatrics and a fellowship in pediatric gastroenterology at Mt. Sinai Hospital in New York. Prior to joining the faculty at University of Medicine and Dentistry of New Jersey, Dr. Rosh served in the Department of Pediatrics at Mt. Sinai Hospital and Columbia Presbyterian Hospital in New York.

About SGX203

SGX203 contains BDP, a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. BDP has been marketed in the United States and worldwide since the early 1970s as the active pharmaceutical ingredient in inhalation products for the treatment of patients with allergic rhinitis and asthma. BDP is also the active ingredient in orBec®, currently in development by Soligenix for the treatment and prevention of acute gastrointestinal Graft-versus-Host disease (GI GVHD). SGX203 is a two pill delivery system of BDP specifically designed for oral use that allows for delivery of BDP throughout the small bowel and the colon. The FDA h
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
11. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) has ... significantly oversubscribed. The issue price under the Placement ... price of QRxPharma shares on 28 September 2010 of A$1.00. ... oversubscriptions from investors and increase the size of the placement from ...
... Radio (Nasdaq: SIRI ) today announced that Andrew ... Center, will host the next edition of his Doctor Radio ... on the link between early antibiotic use in children and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080819/NYTU044LOGO ) Dr. Brotman,s guests will ...
Cached Medicine Technology:QRxPharma Limited Announces A$14 Million Placement Together With a Share Purchase Plan 2QRxPharma Limited Announces A$14 Million Placement Together With a Share Purchase Plan 3SIRIUS XM's Doctor Radio's 'The Dean's List' To Focus On Link Between Early Antibiotic Use In Children And Obesity 2SIRIUS XM's Doctor Radio's 'The Dean's List' To Focus On Link Between Early Antibiotic Use In Children And Obesity 3SIRIUS XM's Doctor Radio's 'The Dean's List' To Focus On Link Between Early Antibiotic Use In Children And Obesity 4
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay ... (IVF) -- the incubation of embryos in a laboratory dish ... vagina, new research suggests. Scientists from the United States ... sharply cut costs for pricey IVF procedures among certain women. ... who don,t live near big-city assisted reproduction centers, the researchers ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... is the must-have source of thousands of facts, figures ... 72 countries and 68 medical sector forecast categories the ... you with global, regional and national views on the ... future outlook. , The report gives you data for ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... that hepatitis C virus infection is a bad ... in renal transplant recipients//. ,Hepatitis C virus (HCV) ... recipients; the prevalence depends on the geographic area. ... renal transplant recipients. ,Researchers from the Armed ...
... Health Minister Anbumani Ramadoss has said that the government is ... and plans to take several steps to check female foeticide, ... ,Dr Ramadoss said that there were plans to set up ... unfortunate practice that prevails on a large scale in the ...
... is to be started by British Heart Foundation to encourage children’s ... the food which will help them to educate about healthier foods//. ... content of the foods they eat. ,More than 10% ... and 37% of children’s were not aware that cheese was made ...
... Institute of Medical Research (QIMR) have found that regular ... which are precursors to skin cancer//. The study was ... Dermatology. ,Aspirin is a cyto-oxygenase (COX) enzyme ... its expression. The COX gene is gene coded which ...
... Clinical Global Health Education was started by Bob Bollinger ... care to patients would improve only if health care ... was to provide training by John Hopkins through Global ... providers. Bollinger said, “Don’t wait for poorly funded medical ...
... Recent research demonstrates that erythrocyte sedimentation rate (ESR) ... haemoglobin concentration significantly influence ESR//. ,The erythrocyte ... the acute phase response. It is helpful in ... to treatment. It is influenced by anaemia, which ...
Cached Medicine News:Health News:John Hopkins CGHH program provides Global Health education 2
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Medicine Products: